479 related articles for article (PubMed ID: 25694099)
1. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
[TBL] [Abstract][Full Text] [Related]
2. Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates.
Alver SK; Lorenz DJ; Marvin MR; Brock GN
Liver Transpl; 2016 Oct; 22(10):1343-55. PubMed ID: 27343202
[TBL] [Abstract][Full Text] [Related]
3. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two equivalent model for end-stage liver disease scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry.
Alver SK; Lorenz DJ; Washburn K; Marvin MR; Brock GN
Transpl Int; 2017 Nov; 30(11):1098-1109. PubMed ID: 28403575
[TBL] [Abstract][Full Text] [Related]
5. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
[TBL] [Abstract][Full Text] [Related]
6. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
Mehta N; Dodge JL; Roberts JP; Yao FY
J Hepatol; 2021 Apr; 74(4):829-837. PubMed ID: 33188904
[TBL] [Abstract][Full Text] [Related]
7. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
Toso C; Dupuis-Lozeron E; Majno P; Berney T; Kneteman NM; Perneger T; Morel P; Mentha G; Combescure C
Hepatology; 2012 Jul; 56(1):149-56. PubMed ID: 22271250
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
Berry K; Ioannou GN
Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
[TBL] [Abstract][Full Text] [Related]
9. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list.
Toso C; Majno P; Berney T; Morel P; Mentha G; Combescure C
Transpl Int; 2014 Jul; 27(7):686-95. PubMed ID: 24649861
[TBL] [Abstract][Full Text] [Related]
10. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
[TBL] [Abstract][Full Text] [Related]
11. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
Mehta N; Dodge JL; Hirose R; Roberts JP; Yao FY
Liver Transpl; 2018 Oct; 24(10):1346-1356. PubMed ID: 30067889
[TBL] [Abstract][Full Text] [Related]
12. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
Mehta N; Dodge JL; Goel A; Roberts JP; Hirose R; Yao FY
Liver Transpl; 2013 Dec; 19(12):1343-53. PubMed ID: 24285611
[TBL] [Abstract][Full Text] [Related]
13. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States.
Heimbach JK; Hirose R; Stock PG; Schladt DP; Xiong H; Liu J; Olthoff KM; Harper A; Snyder JJ; Israni AK; Kasiske BL; Kim WR
Hepatology; 2015 May; 61(5):1643-50. PubMed ID: 25644186
[TBL] [Abstract][Full Text] [Related]
14. Consequences of the implementation of the Model for End-stage Liver Disease system for liver allocation in Brazil.
Pestana RC; Baracat EI; Massarollo PC; Pereira LA; Szutan LA
Transplant Proc; 2013; 45(6):2111-4. PubMed ID: 23747144
[TBL] [Abstract][Full Text] [Related]
15. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
[TBL] [Abstract][Full Text] [Related]
16. Improved waiting-list outcomes in Argentina after the adoption of a model for end-stage liver disease-based liver allocation policy.
Cejas NG; Villamil FG; Lendoire JC; Tagliafichi V; Lopez A; Krogh DH; Soratti CA; Bisigniano L
Liver Transpl; 2013 Jul; 19(7):711-20. PubMed ID: 23775946
[TBL] [Abstract][Full Text] [Related]
17. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy.
Yao FY; Bass NM; Ascher NL; Roberts JP
Liver Transpl; 2004 May; 10(5):621-30. PubMed ID: 15108253
[TBL] [Abstract][Full Text] [Related]
18. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
[TBL] [Abstract][Full Text] [Related]
19. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
Kemmer N; Neff G; Kaiser T; Zacharias V; Thomas M; Tevar A; Satwah S; Shukla R; Buell J
Liver Transpl; 2006 Oct; 12(10):1519-22. PubMed ID: 17004260
[TBL] [Abstract][Full Text] [Related]
20. Higher Mortality in registrants with sudden model for end-stage liver disease increase: Disadvantaged by the current allocation policy.
Massie AB; Luo X; Alejo JL; Poon AK; Cameron AM; Segev DL
Liver Transpl; 2015 May; 21(5):683-9. PubMed ID: 25762287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]